Pertussis (Whooping Cough) - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 8, 5, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pertussis (Whooping Cough) - Overview
Pertussis (Whooping Cough) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pertussis (Whooping Cough) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Bharat Biotech International Ltd
Biological E Ltd
Boryung Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
DBV Technologies SA
GlaxoSmithKline Plc
Green Cross Corp
Indian Immunologicals Ltd
Kaketsuken KK
LG Chem, Ltd.
NanoBio Corp
Sanofi
Sanofi Pasteur SA
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Synthetic Biologics Inc
Zydus Cadila Healthcare Ltd
Pertussis (Whooping Cough) - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(hepatitis B + pertussis) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bladder cancer + pertussis + tuberculosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTaP-IPV-HB-PRPT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis (whole cell) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pertussis (Whooping Cough) - Dormant Projects
Pertussis (Whooping Cough) - Discontinued Products
Pertussis (Whooping Cough) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination
Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough
Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine
Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H1 2017
Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H1 2017
Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H1 2017
Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H1 2017
Pertussis (Whooping Cough) - Pipeline by LG Chem, Ltd., H1 2017
Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H1 2017
Pertussis (Whooping Cough) - Pipeline by Sanofi, H1 2017
Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H1 2017
Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H1 2017
Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Pertussis (Whooping Cough) - Dormant Projects, H1 2017
Pertussis (Whooping Cough) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Pertussis (Whooping Cough) - Discontinued Products, H1 2017